Is Apellis Pharmaceuticals Inc (NASDAQ: APLS) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

APLS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Apellis Pharmaceuticals Inc is $7.09B. A total of 1.24 million shares were traded on the day, compared to an average of 1.57M shares.

In the most recent transaction, Dunlop A. Sinclair sold 18,681 shares of APLS for 57.18 per share on Mar 19 ’24. After the transaction, the Director now owns 173,998 company shares. In a previous transaction on Mar 18 ’24, DeLong Mark Jeffrey sold 9,913 shares at 56.90 per share. APLS shares that Chief Business & Strat Officer owns now total 54,693.

Among the insiders who sold shares, Chopas James George disposed of 184 shares on Mar 15 ’24 at a per-share price of $56.46. This resulted in the VP/Chief Accounting Officer holding 38,883 shares of APLS after the transaction. In another insider transaction, Nicholson Nur sold 11,220 shares at $57.56 per share on Mar 13 ’24. Company shares held by the Chief Technical Officer now total 56,287.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, APLS has a high of $94.75 and a low of $19.83.

As of this writing, APLS has an earnings estimate of -$0.54 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.28 per share and a lower estimate of -$0.88. The company reported an EPS of -$1.17 in the last quarter, which was -37.60% lower than expectations of -$0.85.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. APLS’s latest balance sheet shows that the firm has $700.55M in Cash & Short Term Investments as of fiscal 2021. There were $210.22M in debt and $131.85M in liabilities at the time. Its Book Value Per Share was $1.63, while its Total Shareholder’s Equity was $198.66M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for APLS is Buy with a score of 4.56.

Most Popular

Related Posts